Satoshi Konagai

The Selective Anaplastic Lymphoma Receptor Tyrosine Kinase Inhibitor ASP3026 Induces Tumor Regression and Prolongs Survival in Non–Small Cell Lung Cancer Model Mice

Masamichi Mori, Yoko Ueno, Satoshi Konagai et al. · Molecular Cancer Therapeutics · 2014 · 57 citations · Full text

Eml4 Genes, Immunology, Cancer Biology +16

Abstract 1728: ASP8273, a novel mutant-selective irreversible EGFR inhibitor, inhibits growth of non-small cell lung cancer (NSCLC) cells with EGFR activating and T790M resistance mutations

Hideki Sakagami, Satoshi Konagai, Hiroko Yamamoto et al. · Cancer Research · 2014 · 20 citations

Abstract 1728, Pathology, Cancer Biology +17

Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression

Hiroaki Tanaka, Hideki Sakagami, Naoki Kaneko et al. · Molecular Cancer Therapeutics · 2019 · 17 citations

Abstract A227: Antitumor activities of ASP3026 against EML4-ALK-dependent tumor models.

Sadao Kuromitsu, Masamichi Mori, Itsuo Shimada et al. · Molecular Cancer Therapeutics · 2011 · 16 citations

Inhibitory Activity, Medicine, Pharmacology +15

Abstract 2821: Anti-tumor activity of ASP3026, – A novel and selective ALK inhibitor -

Sadao Kuromitsu, Masamichi Mori, Itsuro Shimada et al. · Cancer Research · 2011 · 14 citations

Cancer Biology, Tumor Biology, Asp3026 Treated-mice +19